Histone deacetylase inhibitors: Highlight on epigenetic regulation;Inhibiteurs des histone-désacétylases: La régulation épigénétique sort de l'ombre

Bulletin du Cancer

Volumn 97, Issue 8, 2010, Pages 917-935

  Pecuchet N ^a   Cluzeau, T ^b   Thibault, C ^a   Mounier, N ^b   Vignot, S ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

Author keywords

Epigenetic regulation; Histone deacetylase; Molecular targeted therapy

Indexed keywords

ANTINEOPLASTIC AGENT; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR;

ACETYLATION; CLASSIFICATION; DRUG EFFECTS; ENZYMOLOGY; GENE EXPRESSION; GENETIC EPIGENESIS; GENETIC TRANSCRIPTION; GENETICS; HUMAN; MUTATION; NEOPLASMS; PHYSIOLOGY; PROMYELOCYTIC LEUKEMIA;

ACETYLATION; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; EPIGENESIS, GENETIC; GENE EXPRESSION; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MUTATION; NEOPLASMS; TRANSCRIPTION, GENETIC;

EID: 77956519074     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2010.1121     Document Type: Review

References (144)

1. Baylin SH. DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet 2000 ; 16 : 168-74.
2. Bird A. DNA methylation patterns and epigenetic memory. Genes Dev 2002 ; 16 : 6-21. (Pubitemid 34049633)
3. Feinberg AP, Tycko B. The history of cancer epigenetics. Nat Rev Cancer 2004 ; 4 : 143-53.
4. Jenuwein T, Allis CD. Translating the histone code. Science 2001 ; 293 : 1074-80.
5. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002 ; 3 : 415-28.
6. Strahl BD, Allis CD. The language of covalent histone modifications. Nature 2000 ; 403 : 41-5.
7. Esteller M. Epigenetics in Cancer. N Engl J Med 2008 ; 358 : 1148-59.
8. Felsenfeld G, Groudine M. Controlling the double helix. Nature 2003 ; 421 : 448-53.
9. Khorasanizadeh S. The nucleosome: from genomic organization to genomic regulation. Cell 2004 ; 116 : 259-72.
10. Johnstone RW. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 2002 ; 1 : 287-99.
11. Van Lint C, Emiliani S, Verdin E. The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Expr 1996 ; 5 : 245-53. (Pubitemid 126682821)
12. Gray SG, Qian CN, Furge K, et al. Microarray profiling of effects of histone deacetylase inhibitors on gene expression in cancer cell lines. Int J Oncol 2004 ; 24 : 773-95.
13. Ellis DJP, Lawman ZK, Bonham K. Histone acetylation is not an accurate predictor of gene expression following treatment with histone deacetylase inhibitors. Biochem Biophys Res Commun 2008 ; 367 : 656-62.
14. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006 ; 9 : 769-84.
15. Dokmanovic M, Clarke C, Marks PA. Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res 2007 ; 5 : 981-9. (Pubitemid 350080267)
16. Yang XJ, Seto E. Lysine acetylation: codified crosstalk with other posttranslational modifications. Mol Cell 2008 ; 31 : 449-61.
17. Spange S, Wagner T, Heinzel T, Kramer OH. Acetylation of non-histone proteins modulates cellular signalling at multiple levels. Int J Biochem Cell Biol 2009 ; 41 : 185-98.
18. de Ruijter AJ, van Gennip AH, Caron HN, Kemp S, van Kuilenburg AB. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 2003 ; 370 : 737-49. (Pubitemid 36399066)
19. Yoshida M, Kijima M, Akita M, Beppu T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin. A. J Biol Chem 1990 ; 265 : 17174-9. (Pubitemid 20334262)
20. Haigis MC, Guarente LP. Mammalian sirtuins-emerging roles in physiology, aging, and calorie restriction. Genes Dev 2006 ; 20 : 2913-21.
21. Yang XJ, Seto E. The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men. Nat Rev Mol Cell Biol 2008 ; 9 : 206-18. (Pubitemid 351301825)
22. Huang Y, Myers SJ, Dingledine R. Transcriptional repression by REST: recruitment of Sin3A and histone deacetylase to neuronal genes. Nat Neurosci 1999 ; 2 : 867-72. (Pubitemid 30602598)
23. Vega RB, Matsuda K, Oh J, Barbosa AC, Yang X, Meadows E, et al. Histone deacetylase 4 controls chondrocyte hypertrophy during skeletogenesis. Cell 2004 ; 119 : 555-66.
24. Dequiedt F, Kasler H, Fischle W, Kiermer V, Weinstein M, Herndier BG, et al. HDAC7, a thymus-specific class II histone deacetylase, regulates Nur77 transcription and TCR-mediated apoptosis. Immunity 2003 ; 18 : 687-98. (Pubitemid 36588585)
25. Kovacs JJ, Murphy PJ, Gaillard S, Zhao X, Wu JT, Nicchitta CV, et al. HDAC6 regulates HSP90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol Cell 2005 ; 18 : 601-7. (Pubitemid 40726236)
26. Messaoudi S, Peyrat JF, Brion JD, Alami M. Recent advances in HSP90 inhibitors as antitumor agents. Anticancer Agents Med Chem 2008 ; 8 : 761-82.
27. Bali P, Pranpat M, Bradner J, Balasis M, Fiskus W, Guo F, et al. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem 2005 ; 280 : 26729-34.
28. Yang Y, Rao R, Shen J, Tang Y, Fiskus W, Nechtman J, et al. Role of acetylation and extracellular location of heat shock protein 90 alpha in tumor cell invasion. Cancer Res 2008 ; 68 : 4833-42.
29. Kopito RR. Aggresomes, inclusion bodies and protein aggregation. Trends Cell Biol 2000 ; 10 : 524-30.
30. Pandey UB. HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS. Nature 2007 ; 447 : 859-63.
31. Kawaguchi Y. The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell 2003 ; 115 : 727-38. (Pubitemid 38030301)
32. Finkel T, Deng CX, Mostoslavsky R. Recent progress in the biology and physiology of sirtuins. Nature 2009 ; 460 : 587-91.
33. He LZ, Tolentino T, Grayson P, Zhong S, Warrell Jr. RP, Rifkind RA, et al. Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. J Clin Invest 2001 ; 108 : 1321-30. (Pubitemid 33107760)
34. Ropero S, Fraga MF, Ballestar E, Hamelin R, Yamamoto H, Boix-Chornet M, et al. A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition. Nat Genet 2006 ; 38 : 566-9.
35. Ropero S, Ballestar E, Alaminos M, Arango D, Schwartz Jr. S, Esteller M. Transforming pathways unleashed by a HDAC2 mutation in human cancer. Oncogene 2008 ; 27 : 4008-12. (Pubitemid 351913637)
36. Choi JH, Kwon HJ, Yoon BI, Kim JH, Han SU, Joo HJ, et al. Expression profile of histone deacetylase 1 in gastric cancer tissues. Jpn J Cancer Res 2001 ; 92 : 1300-4.
37. Weichert W, Roske A, Gekeler V, Beckers T, Ebert MP, Pross M, et al. Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. Lancet Oncol 2008 ; 9 : 139-48.
38. Zhu P, Martin E, Mengwasser J, Schlag P, Janssen KP, Gottlicher M. Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell 2004 ; 5 : 455-63. (Pubitemid 38610247)
39. Marquard L, Gjerdrum LM, Christensen IJ, Jensen PB, Sehested M, Ralfkiaer E. Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma. Histopathology 2008 ; 53 : 267-77.
40. Weichert W, Roske A, Niesporek S, Noske A, Buckendahl AC, Dietel M, et al. Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo. Clin Cancer Res 2008 ; 14 : 1669-77.
41. Weichert W, Roske A, Gekeler V, Beckers T, Stephan C, Jung K, et al. Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br J Cancer 2008 ; 98 : 604-10.
42. Krusche CA, Wulfing P, Kersting C, Vloet A, Bocker W, Kiesel L, et al. Histone deacetylase-1 and -3 protein expression in human breast cancer: a tissue microarray analysis. Cancer Res Treat 2005 ; 90 : 15-23.
43. Bicaku E, Marchion DC, Schmitt ML, Munster PN. Selective inhibition of histone deacetylase 2 silences progesterone receptor-mediated signaling. Cancer Res 2008 ; 68 : 1513-9.
44. Jeong JW, Bae MK, Ahn MY, Kim SH, Sohn TK, Bae MH, et al. Regulation and destabilization of HIF-1 alpha by ARD1-mediated acetylation. Cell 2002 ; 111 : 709-20.
45. Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007 ; 37 : 5541-52.
46. Dedes KJ, Dedes I, Imesch P, et al. Acquired vorinostat resistance shows partial cross-resistance to 'second-generation' HDAC inhibitors and correlates with loss of histone acetylation and apoptosis but not with altered HDAC and HAT activities. Anticancer Drugs 2009 ; 20 : 321-33.
47. Kelly WK, Richon VM, O'Connor O, et al. Phase I clinical trial of histone deacatylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res 2003 ; 9 : 3578-88.
48. Kelly WK, O'Connor O, Krug LM, Chiao JH, Heaney M, Curley T, et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 2005 ; 23 : 3923-31.
49. Duvic M, Talpur R, Ni X, Zhang C, Hazarika P, Kelly C, et al. Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 2007 ; 109 : 31-9.
50. Olsen EA, Kim YH, Kuzel TM, Pacheco TR, Foss FM, Parker S, et al. Phase IIB multicenter trial of vorinostat in patients with persistent, progressive or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 2007 ; 25 : 3109-15.
51. Garcia-Manero G, Yang H, Buesos-Ramos C, Al E. Phase I study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid, [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood 2008 ; 111 : 1060-6.
52. Kirschbaum MH, Popplewell L, Nademanee A, Pullakart V, Delioukina M, Zain J, et al. A phase II study of vorinostat (suberoylanilide hydroxamic acid, SAHA) in relapsed or refractory indolent non-hodgkin's lymphoma. A California Cancer Consortium study [abstract]. Haematologica 2009 ; 94(Suppl 2) : 0409.
53. Traynor AM, Dubey S, Eickhoff JC, Kolesar JM, Schell K, Huie MS, et al. Vorinostat (NSC# 701852) in patients with relapsed non-small lung cancer: a Wisconsin Oncology Network phase II study. J Thorac Oncol 2009 ; 4 : 522-6.
54. Vansteenkiste J, Van Custem E, Dumez H, Chen C, Ricker JL, Randolph SS, et al. Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer. Invest New Drugs 2008 ; 26 : 483-8.
55. Woyach JA, Kloos RT, Ringel MD, Arbogast D, Collamore M, Zwiebel JA, et al. Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma. J Clin Endocinol Metab 2009 ; 94 : 164-70.
56. Galanis E, Jaeckle KA, Maurer MJ, Reid JM, Ames MM, Hardwick JS, et al. Phase II trial of vorinostat in recurrent gliblastoma multiforme: a north central cancer treatment group study. J Clin Oncol 2009 ; 27 : 2052-8.
57. Luu TH, Morgan RJ, Leong L, Lim D, McNamara M, Portnow J, et al. A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study. Clin Cancer Res 2008 ; 14 : 7138-42.
58. Blumenschein GRJ, Kies MS, Papadimitrakopoulou VA, Lu C, Kumar AJ, Ricker JL, et al. Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanililide hydroxamic acid, SAHA) in patients with recurrent and/or metastasic head and neck cancer. Invest New Drugs 2008 ; 26 : 81-7.
59. Modesitt SC, Sill M, Hoffman JS, Bender DP, Gynecologic Oncology Group. A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2008 ; 109 : 182-6.
60. Bradley D, Rathkopf D, Dunn R, Stadler WM, Liu G, Smith DC, et al. Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862). Cancer 2009 : 9999 NA.
61. Steele NL, Plumb JA, Vidal L, Tjornelund J, Knoblauch P, Rasmussen A, et al. A phase I pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clin Cancer Res 2008 ; 14 : 804-10.
62. Gimsing P, Hansen M, Knudsen LM, Knoblauch P, Christensen IJ, Ooi CE, et al. A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia. Eur J Haematol 2008 ; 81 : 170-6.
63. Kelly WK, DeBono J, Blumenschein G, Lassen U, Zain J, O'Connor O, et al. Final results of a phase I study of oral belinostat (PXD101) in patients with solid tumors. J Clin Oncol 2009 ; 27 : 3531 (Meeting Abstracts).
64. Zain JM, Foss F, Kelly WK, DeBono J, Petrylak D, Narwal A, et al. Final results of a phase I study of oral belinostat (PXD101) in patients with lymphoma. J Clin Oncol 2009 ; 27 : 8580 (Meeting Abstracts).
65. Giaccone G, Rajan A, Carter C, Kelly R, Berman A, Spittler J, et al. Phase II study of the histone deacetylase inhibitor belinostat in thymic malignancies. J Clin Oncol 2009 ; 27 : 7589 (Meeting Abstracts).
66. Giles F, Fischer T, Cortes J, Garcia-Manero G, Beck J, Ravandi F, et al. A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res 2006 ; 12 : 4628-35.
67. Zhang L, Lebwohl D, Masson E, Laird G, Cooper MR, Prince HM, et al. Clinically relevant QTc prolongation is not associated with current dose schedules of LBH589 (panobinostat). J Clin Oncol 2008 ; 26 : 332-3 (discussion 333-4).
68. Sharma S, Vogelzang NJ, Beck J. Phase I pharmacokinetic and pharmacodynamic study of once-weekly i.v. panobinostat (LBH589) [abstract]. ECCO Annual Meeting Abstracts 2007.
69. Prince HM, George D, Patnaik A. Phase I study of oral LBH589, a novel deacetylase (DAC) inhibitor in advanced solid tumors and non-hodgkin's lymphoma (abstract). J Clin Oncol 2007 ; 25 (Suppl 18) : 3500 (Meeting Abstracts).
70. Duvic M, Becker JC, Dalle S. Phase II trial of oral panobinostat (LBH589) in patients with refractory cutaneous T-cell lymphoma (CTCL) (abstract). ASH Annual Meeting Abstracts 2008 ; 112 : 1005.
71. Dickinson M, Ritchie D, Deangelo DJ, Spencer A, Ottmann OG, Fischer T, et al. Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin lymphoma. Br J Haematol 2009 ; 147 : 97-101.
72. Wolf JL, Siegel D, Matous J. A phase II study of oral panobinostat (LBH589) in adult patients with advanced refractory multiple myeloma (abstract). ASH Annual Meeting Abstracts 2008 ; 112 : 2781.
73. Okamoto N, Hatake K, Yamamoto N. A phase I study of oral panobinostat (LBH589) in Japanese patients with advances solid tumors (abstract). EORTC-NCI-AACR Annual Meeting 2008.
74. Ottmann OG, Spencer A, Prince HM, Bhalla KN, Fischer T, Liu A, et al. Phase IA/II Study of Oral Panobinostat (LBH589), a novel pan-deacetylase inhibitor (DACi) demonstrating efficacy in patients with advanced heamatologic malignancies (abstract). ASH Annual Meeting Abstracts 2008 ; 112 : 958.
75. Woo MM, Culver K, Li W, Liu A, Scott JW, Parker K, et al. Panobinostat (LBH589) pharmacokinetics (PK): implication for clinical safety and efficacy. Ann Oncol 2008 ; 18 : 487P.
76. de Bono J, Brunetto AT, Kristeleit R, Mais A, Hauns B, Hentsch B. Clinical and preclinical development of 4SC-201, a new oral histone deacetylase (HDAC) inhibitor. Eur J Cancer Suppl 2009 ; 7 : 137.
77. Furumai R, Matsuyama A, Kobashi N, Lee KH, Nishiyama M, Nakajima H, et al. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res 2002 ; 62 : 4916-21.
78. Sandor V, Bakke S, Robey RW, Kang MH, Blagosklonny MV, Bender J, et al. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res 2002 ; 8 : 718-28.
79. Marshall JL, Rizvi N, Kauh J, Dahut W, Figuera M, Kang MH, et al. A phase I trial of depsipeptide (FR901228) in patients with advanced cancer. J Exp Ther Oncol 2002 ; 2 : 325-32.
80. Cabell C, Bates S, Piekarz R, Whittaker S, Kim Y, Godfrey C, et al. Systematic assessment of potential cardiac effects of the novel histone deacetylase (HDAC) inhibitor romidepsin. J Clin Oncol 2009 ; 27 : 19533 (Meeting Abstracts).
81. Shah MH, Binkley P, Chan K, Xiao J, Arbogast D, Collamore M, et al. Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors. Clin Cancer Res 2006 ; 12 : 3997-4003.
82. Bates SE, Rosing DR, Fojo T, Piekarz RL. Challenges of evaluating the cardiac effects of anticancer agents. Clin Cancer Res 2006 ; 12 : 3871-4.
83. Molife LR, Attard G, Fong PC, Karavasilis V, Reid AH, Patterson S, et al. Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC). Ann Oncol 2010 ; 21 : 109-13.
84. Stadler WM, Margolin K, Ferber S, McCulloch W, Thompson JA. A phase II study of depsipeptide in refractory metastatic renal cell cancer. Clin Genitourin Cancer 2006 ; 5 : 57-60.
85. Whitehead RP, Rankin C, Hoff PM, Gold PJ, Billingsley KG, Chapman RA, et al. Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336). Invest New Drugs 2008 ; 27 : 469-75.
86. Piekarz RL, Frye R, Turner M, Wright JJ, Allen SL, Kirschbaum MH, et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol 2009 ; 27 : 5410-7.
87. Piekarz R, Frye R, Wright J, Figg W, Allen S, Kirschbaum M, et al. Update of the NCI multiinstitutional phase II trial of romidepsin, FK228, for patients with cutaneous or peripheral T-cell lymphoma. J Clin Oncol 2007 ; 25 : 8027 (Meeting Abstracts).
88. Dermierre M, Whittaker S, Kim Y, Kim E, Piekarz R, Prince M, et al. Pooled analyses of two international, multicenter clinical studies of romidepsin in 167 patients with cutaneous T-cell lymphoma (CTCL). J Clin Oncol 2009 ; 27 : 8546 (Meeting Abstracts).
89. Klimek VM, Fircanis S, Maslak P, Guernah I, Baum M, Wu N, et al. Tolerability, pharmacodynamics and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes. Clin Cancer Res 2008 ; 14 : 826-32.
90. Byrd JC, Marcucci G, Parthun MR, Xiao JJ, Klisovic RB, Moran M, et al. A phase I and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood 2005 ; 105 : 959-67.
91. Sherman EJ, Fury G, Tuttle RM, Ghossein R, Stambuk H, Baum M, et al. Phase II study of depsipeptide (DEP) in radioiodine (RAI)-refractory metastatic nonmedullary thyroid carcinoma. J Clin Oncol. 2009 ; 27 : (suppl; abstr 6059).
92. Bonfils C, Kalita A, Dubay M, Siu LL, Carducci MA, Reid G, et al. Evaluation of the pharmacodynamic effects of MGCD0103 from preclinical models to human using a novel HDAC enzyme assay. Clin Cancer Res 2008 ; 14 : 3441-9.
93. Bociek RG, Kuruvilla J, Pro B, Wedgwood A, Li Z, Drouin M, et al. Isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 demonstrates clinical activity and safety in patients with relapsed/refractory classical Hodgkin lymphoma (HL). J Clin Oncol 2008 ; 20 : 8507 (Meeting Abstracts).
94. Marchion DC, Bicaku E, Daud A, Sullivan DM, Munster PN. In vivo synergy between topoisomerase II and histone deacatylase inhibitors: predictive correlates. Mol Cancer Ther 2005 ; 4 : 1993-2000.
95. Arnold NB, Arkus N, Gunn J, Korc M. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances gemcitabine-induced cell death in pancreatic cancer. Clin Cancer Res 2007 ; 13 : 18-26.
96. Hurwitz H, Nelson B, O'Dwyer PJ, Chiorean EG, Gabrail N, Li Z, et al. Phase I/II: The oral isotype-selective HDAC inhibitor MGCD0103 in combination with gemcitabine (Gem) in patients (pts) with refractory solid tumors. J Clin Oncol (Meeting Abstracts) 2008 ; 26 : abstr 4625.
97. Northfelt DW, Bonnem E, Fagerberg J, Von Hoff D, Grem J. Belinostat (Bel) down-regulates thymidylate synthase (TS) in tumor tissue: a dose-escalation study of belinostat alone and in combination with 5-fluorouracil (5-FU) (abstract). Gastrointestinal Cancers Symposium 2009; 333.
98. Munster P, Marchion D, Bicaku E, Lacevic M, Kim J, Centeno B, et al. Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FEC. Clin Cancer Res 2009 ; 15 : 2488-96.
99. Kim MS, Blake M, Baek JH, Kohlhagen G, Pommier Y, Carrier F. Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res 2003 ; 63 : 7291-300.
100. Vaishampayan U, Rathkopf D, Chi KN, et al. Phase IB dose-finding trial of intravenous (i.v.) panobinostat (PAN) with docetaxel (DOC) and prednisone (PRED) in patients (pts) with castration resistant prostate cancer (CRPC). Eur J Cancer Suppl 2009 ; 7 : 413.
101. Dowdy SC, Jiang S, Zhou XC, Hou X, Jin F, Podratz KC. Histone deacetylase inhibitors and paclitaxel cause synergistic effects on apoptosis and microtubule stabilization in papillary serous endometrial cancer cells. Mol Cancer Ther 2006 ; 5 : 2767-76.
102. Ramalingam SS, Parise RA, Ramanathan RK, Lagattuta TF, Musguire LA, Stoller RG, et al. Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies. Clin Cancer Res 2007 ; 13 : 3605-10.
103. Owonikoko TK, Ramalingam SS, Kanterewicz B, et al. Vorinostat increases carboplatin and paclitaxel activity in non-small cell lung cancer cells. Int J Cancer 2009.
104. Belani C, Ramalingam S, Kalemkerian G, Mok T, Rosell R, Ahn MJ, et al. Randomized, double blind phase II/III study of first-line paclitaxel (P) plus carboplatin (C) in combination with vorinostat or placebo in patients with advanced non-small cell lung cancer (NSCLC) (abstract). Eur J Cancer Suppl 2009 ; 7 : 507.
105. Ramalingam SS, Maitland ML, Frankel P, Argiris AE, Koczywas M, Gitlitz B, et al. Carboplatin and paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small cell lung cancer. J Clin Oncol 2010 ; 28 : 56-62.
106. Rikiishi H, Shinohara F, Sato T, Suzuki M, Echigo S. Chemosensitization of oral squamous cell carcinoma cells to cisplatin by histone deacetylase inhibitor, suberoylanilide hydroxamic acid. Int J Oncol 2007 ; 30 : 1181-8.
107. Dong G, Luo J, Kumar V, Dong Z. Inhibitors of histone deacetylases suppress cisplatin-induced p53 activation and apoptosis in renal tubular cells. Am J Physiol Renal Physiol 2009 ; 298 : 293-300.
108. Chen L, Vogelzang NJ, Blumenschein G, Robert F, Pluda JM, Frankel SR, et al. Phase I trial of vorinostat (V) in combination with pemetrexed (Pem) and cisplatin (CDDP) in patients with advanced cancer. J Clin Oncol 2007 ; 25 : 18088 (Meeting Abstracts).
109. Teixeira L, Descourt R, Moro-Sibilot D, Misset JL, Gachard E, Rizvi S, et al. Phase I dose-escalation study of vorinostat in combination with gemcitabine and cisplatinum in patients with advanced non-small cell lung cancer (NSCLC). Eur J Cancer Suppl 2009 ; 7 : 554.
110. Thomas S, Munster PN. Histone deacetylase inhibitor induced modulation of anti-estrogen therapy. Cancer Lett 2009 ; 280 : 184-91.
111. Munster PN, Lacevic M, Thomas S, Christian C, Ismail-Khan R, Melisko M, et al. Phase II trial of the histone deacetylase inhibitor, vorinostat, to restore hormone sensitivity to the antiestrogen tamoxifen in patients with advanced breast cancer who progressed on prior hormone therapy. J Clin Oncol 2009 ; 27 : 1075 (Meeting Abstracts).
112. Reguart N, Isla D, Cardona AF, Palmero R, Cardenal F, Rolfo C, et al. Phase I trial of vorinostat in combination with erlotinib for advanced non-small cell lung cancer (NSCLC) patients (pts) with EGFR mutations after erlotinib progression (NCT00503971): the TARZO trial. Eur J Cancer Suppl 2009 ; 7 : 550.
113. Konduri K, Spira AI, Jotte RM, Boyd T, Gaffar YA, Reynolds C, et al. Results from a phase I safety lead-in study investigating the combination of erlotinib and the histone deacetylase inhibitor entinostat in patients with advanced NSCLC (abstract). J Clin Oncol 2009 ; 27 : 14545 (Meeting Abstracts).
114. Bali P, Pranpat M, Swaby R, Fiskus W, Yamaguchi H, Balasis M, et al. Activity of suberoylanilide hydroxamic Acid against human breast cancer cells with amplification of HER2. Clin Cancer Res 2005 ; 11 : 6382-9.
115. Conte P, Campone M, Pronzato P, Amadori D, Frank R, Schuetz F, et al. Phase I trial of panobinostat (LBH589) in combination with trastuzumab in pretreated HER2-positive metastatic breast cancer (mBC): Preliminary safety and tolerability results. J Clin Oncol 2009 ; 27 : 1081S (Meeting Abstracts).
116. Pili R, Wilky B, Salumbides B, Hammers H, Holleran JL, Egorin MJ, et al. Phase I/II trial of the histone deacetylase inhibitor vorinostat in combination with bevacizumab in patients with renal cell carcinoma: phase I safety and pharmacokinetic/pharmacodynamic results. In Genitourinary Cancers Symposium, Edition 2008; 371S.
117. Nawrocki ST, Carew JS, Pino MS, et al. Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells. Cancer Res 2006 ; 66 : 3773-81.
118. Pei XY, Dai Y, Grant S. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clin Cancer Res 2004 ; 10 : 3839-52.
119. Weber D, Badros AZ, Jagannath S, Siegel D, Richon V, Rizvi S, et al. Vorinostat plus bortezomib for the treatment of relapsed/ refractory multiple myeloma: early clinical experience. Blood 2008 ; 112 : 871 (ASH Annual Meeting Abstracts).
120. Badros AZ, Philip S, Niesvizk R, Goloubeva O, Harris C, Zweibel J, et al. Phase I trial of vorinostat plus bortezomib (bort) in relapsed/refractory multiple myeloma (mm) patients (pts). J Clin Oncol 2008 ; 26 : 8548 (Meeting Abstracts).
121. Berenson JR, Yellin O, Mapes R, Eades B, Abaya CD, Strayer A, et al. A phase II study of a 1-hour infusion of romidepsin combined with bortezomib for multiple myeloma (MM) patients with relapsed or refractory disease. J Clin Oncol 2009 ; 27 : 19508 (Meeting Abstracts).
122. Rahmani M, Yu C, Dai Y, Reese E, Ahmed W, Dent P, et al. Coadministration of the heat shock protein 90 antagonist 17-allylamino-17-demethoxygeldanamycin with suberoylanilide hydroxamic acid or sodium butyrate synergistically induces apoptosis in human leukemia cells. Cancer Res 2003 ; 63 : 8420-7.
123. Insinga A, Monestiroli S, Ronzoni S, Gelmetti V, Marchesi F, Viale A, et al. Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med 2005 ; 11 : 71-6.
124. Frew AJ, Lindemann RK, Martin BP, Clarke CJ, Sharkey J, Anthony DA, et al. Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist. Proc Natl Acad Sci U S A 2008 ; 105 : 11317-22.
125. Cimino G, Lo-Coco F, Fenu S, Travaglini L, Finolezzi E, Mancini M, et al. Sequential valproic acid/all-trans retinoic acid treatment reprograms differentiation in refractory and high-risk acute myeloid leukemia. Cancer Res 2006 ; 66 : 8903-11.
126. Kuendgen A, Schmid M, Schlenk R, Knipp S, Hildebrandt B, Steidl C, et al. The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia. Cancer 2006 ; 106 : 112-9.
127. Soriano AO, Yang H, Faderl S, Estrov Z, Giles F, Ravandi F, et al. Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood 2007 ; 110 : 2302-8.
128. Blum W, Klisovic RB, Hackanson B, Liu Z, Liu S, Devine H, et al. Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. J Clin Oncol 2007 ; 25 : 3884-91.
129. Juergens RA, Vendetti F, Coleman B, Sebree RS, Rudek MA, Belinsky S, et al. Interim analysis of a phase II trial of 5-azacitidine (5AC) and entinostat (SNDX-275) in relapsed advanced lung cancer (NSCLC). J Clin Oncol 2009 ; 27 : 8055 (Meeting Abstracts).
130. Dejligbjerg M, Grauslund M, Litman T, Collins L, Qian X, Jeffers M, et al. Differential effects of class I isoform histone deacetylase depletion and enzymatic inhibition by belinostat or valproic acid in HeLa cells. Mol Cancer 2008 ; 7 : 70.
131. Fantin VR, Loboda A, Paweletz CP, Hendrickson RC, Pierce JW, Roth JA, et al. Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma. Cancer Res 2008 ; 68 : 3785-94.
132. Ellis L, Pan Y, Smyth GK, George DJ, McCormack C, Williams-Truax R, et al. Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma. Clin Cancer Res 2008 ; 14 : 4500-10.
133. Fotheringham S, Epping MT, Stimson L, Khan O, Wood V, Pezzella F, et al. Genome-wide loss-of-function screen reveals an important role for the proteasome in HDAC inhibitor-induced apoptosis. Cancer Cell 2009 ; 15 : 57-66.
134. Miyanaga A, Gemma A, Noro R, Kataoka K, Matsuda K, Nara M, et al. Antitumor activity of histone deacetylase inhibitors in non-small cell lung cancer cells: development of a molecular predictive model. Mol Cancer Ther 2008 ; 7 : 1923-30.
135. Doss HH, Jones SF, Infante JR, Spigel DR, Willcutt N, Lamar R, et al. A phase I trial of romidepsin in combination with gemcitabine in patients with pancreatic and other advanced solid tumors. J Clin Oncol 2008 ; 26 : 2567S (Meeting Abstracts).
136. Sinha R, Moliffe R, Scurr M, Vidal L, Engelholm SA, Buhl Jensen P, et al. A phase I/II study of the safety and anti-cancer activity of i.v. administered belinostat (PXD101) plus carboplatin (C) or paclitaxel (P), or both in patients with advanced solid tumors. J Clin Oncol 2007 ; 25 : 3574 (Meeting Abstracts).
137. Finkler NJ, Dizon DS, Braly P, Micha J, Lassen U, Celano P, et al. Phase II multicenter trial of the histone deactylase inhibitor (HDACi) belinostat, carboplatin and paclitaxel (BelCaP) in patients (pts) with relapsed epithelial ovarian cancer (EOC). J Clin Oncol 2008 ; 26 : 5519 (Meeting Abstracts).
138. Siegel D, Sezer O, San Miguel JF, Mateos MV, Prosser I, Cavo M, et al. A phase IB, multicenter, open-label, dose-escalation study of oral panobinostat (LBH589) and i.v. bortezomib in patients with relapsed multiple myeloma. Blood 2008 ; 112 : 2781 (ASH Annual Meeting Abstracts).
139. Harrison SJ, Quach H, Yuen K, Strayer A, Copeman MC, Peinert S, et al. High response rates with the combination of bortezomib, dexamethasone and the pan-histone deacetylase inhibitor romidepsin in patients with relapsed or refractory multiple myeloma in a phase I/II clinical trial. Blood 2008 ; 112 : 3698 (ASH Annual Meeting Abstracts).
140. Spencer A, Taylor K, Lonial S, Mateos MV, Jalaluddin M, Hazell K, et al. Panobinostat plus lenalidomide and dexamethasone phase I trial in multiple myeloma (MM). J Clin Oncol 2009 ; 27 : 8542 (Meeting Abstracts).
141. Silverman LR, Verma A, Odchimar-Reissig R. A phase I/II study of vorinostat, an oral histone deacetylase inhibitor, in combination with azacitidine in patients with the myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Initial results of the phase I trial: a New York Cancer Consortium. J Clin Oncol 2008 ; 26 : 7000 (Meeting Abstracts).
142. Garcia-Manero G, Yang AS, Klimek V. Phase I/II study of a novel oral isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 in combination with azacitidine in patients (pts) with high-risk myelodysplatic syndrome (MDS) or acute leukemia (AML). J Clin Oncol 2007 ; 25 : 7062 (Meeting Abstracts).
143. Gore SD, Jiemjit A, Silverman LB. Combines methyltransferase/ histone deacetylase inhibition with 5-azacitidine and MS-275 in patients with MDS, CMMol and AML: clinical response, histone acetylation and DNA damage. ASH Annual Meeting Abstracts 2006 ; 108 : 517.
144. Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, Yang H, Rosner G, Verstovsek S, et al. Phase I/II study of the combination of 5-aza-2′- deoxycytidine with valproic acid in patients with leukemia. Blood 2006 ; 108 : 3271-9.